Welcome to our dedicated page for Shuttle Pharmaceuticals Holdings news (Ticker: SHPH), a resource for investors and traders seeking the latest updates and insights on Shuttle Pharmaceuticals Holdings stock.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) is a clinical stage pharmaceutical company pioneering innovative therapies aimed at curing cancers. Founded in 2012 by faculty members from Georgetown University Medical Center, Shuttle Pharma focuses on developing radiation sensitizers to enhance the efficacy of radiation therapy (RT). The company’s mission is to improve cancer treatment outcomes, prolong patient survival, and elevate the quality of life for those undergoing therapy.
Shuttle Pharma's flagship product, Ropidoxuridine (IPdR), is a leading candidate designed to be used in combination with RT for treating glioblastoma, a lethal brain tumor currently without a cure. The company has received positive feedback from the U.S. Food and Drug Administration (FDA), including a 'Safe to Proceed' letter, enabling the commencement of Phase II clinical trials. The FDA's guidance has paved the way for Shuttle Pharma to develop Ropidoxuridine further as a radiation sensitizer.
In addition to Ropidoxuridine, Shuttle Pharma is advancing its predictive biomarker program for prostate cancer. This initiative includes licensing intellectual property from Georgetown University to develop diagnostic blood tests. These tests aim to predict the success or failure of RT in prostate cancer patients, thereby informing treatment decisions and improving patient management.
Shuttle Pharma operates with a strong collaborative ethos, partnering with academic institutions and leveraging grant funding from entities like the National Institutes of Health (NIH). The company’s research also extends to histone deacetylase (HDAC) inhibitors, such as its lead HDAC6 inhibitor candidate, SP-2-225, which aims to prevent tumor relapse and enhance antitumor immune responses.
Financially, Shuttle Pharma is actively involved in capital raising initiatives to support its ambitious research and development goals. A recent Rights Offering aims to raise up to $4.5 million, supplementing the company’s resources to advance its clinical trials and diagnostic programs.
Overall, Shuttle Pharmaceuticals Holdings, Inc. is at the forefront of developing groundbreaking therapies that could revolutionize cancer treatment by making radiation therapy more effective and less toxic.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) announced a research agreement with Georgetown University to evaluate its lead HDAC6 inhibitor candidate, SP-2-225. The collaboration will focus on the anti-tumor effects of SP-2-225 in combination with radiation therapy (RT) using a breast cancer model. The research aims to support IND-enabling studies in 2023 with plans for a Phase I clinical trial in 2024. SHPH's pipeline includes Ropidoxuridine, aimed at enhancing cancer cell sensitivity to RT, which is progressing towards Phase II testing in brain cancer patients. This partnership underscores SHPH's commitment to improving cancer treatment outcomes.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) reported a corporate update on March 15, 2023, in conjunction with its Annual Report on Form 10-K for the fiscal year ending December 31, 2022. The company raised $11.5 million through its IPO and $4.3 million through a private placement. It is preparing for a Phase II clinical trial of its lead drug candidate, Ropidoxuridine, aimed at enhancing outcomes for glioblastoma patients undergoing radiation therapy. With a cash balance of $8.4 million as of December 31, 2022, and recent funding, Shuttle anticipates sufficient capital to support operations through Q4 2025.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) announced a partnership with the University of Iowa Pharmaceuticals for the formulation development and clinical batch manufacturing of Ropidoxuridine. This step is crucial for their upcoming Phase II clinical trial aimed at glioblastoma treatment, expected to be submitted to the FDA by Q2 2023. The company has manufactured approximately 10,000 capsules for the trial, working alongside TCG GreenChem, Inc. With over 800,000 patients annually receiving radiation therapy in the U.S., Shuttle's focus on radiation sensitizers positions it to address significant market needs in oncology.
FAQ
What is the current stock price of Shuttle Pharmaceuticals Holdings (SHPH)?
What is the market cap of Shuttle Pharmaceuticals Holdings (SHPH)?
What does Shuttle Pharmaceuticals Holdings, Inc. specialize in?
What is Ropidoxuridine?
What is the significance of the FDA's 'Safe to Proceed' letter for Shuttle Pharmaceuticals?
How is Shuttle Pharmaceuticals advancing prostate cancer treatment?
What types of cancer therapies is Shuttle Pharma developing?
What collaboration does Shuttle Pharma have with Georgetown University?
What are the financial strategies of Shuttle Pharmaceuticals?
What is the company's mission?
What other cancers besides glioblastoma is Shuttle Pharma targeting?